MedMira (MedMira) Net Change in Cash : $0.53 Mil (TTM As of Jan. 2024)

View and export this data going back to . Start your Free Trial

What is MedMira Net Change in Cash?

Net Change in Cash is calculated as the total of Cash Flow from Operations , Cash Flow from Investing, Cash Flow from Financing, and Effect of Exchange Rate Changes.

MedMira's Net Change in Cash for the three months ended in Jan. 2024 was $-0.03 Mil. Its Net Change in Cash for the trailing twelve months (TTM) ended in Jan. 2024 was $0.53 Mil.

MedMira Net Change in Cash Historical Data

The historical data trend for MedMira's Net Change in Cash can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MedMira Net Change in Cash Chart

MedMira Annual Data

Trend

Jul14

Jul15

Jul16

Jul17

Jul18

Jul19

Jul20

Jul21

Jul22

Jul23

Net Change in Cash

Get a 7-Day Free Trial

0.07

0.23

-0.32

0.03

-0.02

MedMira Quarterly Data
	Apr19	Jul19	Oct19	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24
Net Change in Cash	Get a 7-Day Free Trial															0.08	-0.03	-0.05	0.64	-0.03

MedMira Net Change in Cash Calculation

MedMira's Net Change in Cash for the fiscal year that ended in Jul. 2023 is calculated as

Net Change in Cash	=	Cash Flow from Operations	+	Cash Flow from Investing	+	Cash Flow from Financing	+	Effect of Exchange Rate Changes
	=	-0.96	+	-0.001	+	0.945	+	0
	=	-0.02

MedMira's Net Change in Cash for the quarter that ended in Jan. 2024

Net Change in Cash = Cash Flow from Operations + Cash Flow from Investing + Cash Flow from Financing + Effect of Exchange Rate Changes

= -0.402 + -0.002 + 0.376 + 0

= -0.03

Net Change in Cash for the trailing twelve months (TTM) ended in Jan. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.53 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

MedMira Net Change in Cash Related Terms
Thank you for viewing the detailed overview of MedMira's Net Change in Cash provided by GuruFocus.com. Please click on the following links to see related term pages.

MedMira (MedMira) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MedMira Inc (OTCPK:MMIRF) » Definitions » Net Change in Cash

Comparable Companies

TSX:MSCL XCNQ:DTC TSX:HBP TSX:BCT TSX:MBX TSXV:NRX TSXV:GSD XCNQ:GLAB TSXV:TTI TSXV:COV OCSE:NOVO B VRTX REGN ASX:CSL MRNA XKRX:207940 XKRX:068270 XBRU:UCB XBRU:ARGX BNTX

Traded in Other Exchanges

47M:Germany MIR:Canada

Address

155 Chain Lake Drive, Suite 1, Halifax, NS, CAN, B3S 1B3

Website

https://www.medmira.com

MedMira Inc is a biotechnology company that is engaged in the business of research, development, and manufacturing of rapid diagnostics and technologies. The company has one reportable operating segment, rapid diagnostic products and services. The product line of the company includes RevealHIV which detects antibodies to HIV-1 and HIV-2 in whole blood, serum or plasma; H Pylori which detects antibodies in serum, plasma, and whole blood; syphilis which detects treponema pallidum antibodies in serum, plasma, and whole blood; among other products. The company generates revenue geographically from North America, Europe, Asia pacific. The majority of the revenue is generated from North America.

MedMira (MedMira) Headlines

From GuruFocus

MedMira Reports First Quarter Results FY2023
By ACCESSWIRE ACCESSWIRE • 12-31-2022

MedMira Closes New Equity Investment for Future Growth
By GlobeNewswire GlobeNewswire • 07-15-2021

MedMira Reports First Quarter Results FY2022
By GlobeNewswire GlobeNewswire • 12-31-2021

Point-of-Care Diagnostic for Trichomonas Vaginalis Based on MedMira's RVF Technology(R)
By ACCESSWIRE ACCESSWIRE • 01-04-2023

Progress Update on Securities
By ACCESSWIRE • 08-31-2023

MedMira receives CE mark for its VYRA(TM) CoV2Flu Antigen Test
By ACCESSWIRE ACCESSWIRE • 01-11-2023

MedMira Reports Third Quarter Results FY2022
By GlobeNewswire GlobeNewswire • 06-30-2022

MedMira Reports First Quarter Results FY2024
By ACCESSWIRE • 12-30-2023

Webb Diagnostic Technologies to Market Rapid Total Antibody Test
By PRNewswire PRNewswire • 04-23-2020

MedMira Reports Third Quarter Results
By GlobeNewswire GlobeNewswire • 06-30-2018